If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
=== Antipsychotics === Many antipsychotics bind to and modulate serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors, among others. Activation of serotonin 5-HT1A receptors and blockade of serotonin 5-HT2A receptors may contribute to the therapeutic antipsychotic effects of these agents, whereas antagonism of serotonin 5-HT2C receptors has been especially implicated in side effects of antipsychotics.
== E == Ehrlichia Ehrlichia chaffeensis Ehrlichia ewingii Eikenella corrodens Elizabethkingia Elizabethkingia meningoseptica Elizabethkingia anophelis Enterobacter Enterobacter aerogenes Enterobacter cloacae Enterococcus Enterococcus avium Enterococcus casseliflavus Enterococcus durans Enterococcus faecalis Enterococcus faecium Enterococcus gallinarum Enterococcus malodoratus Escherichia coli Escherichia coli O157:H7
N-Desethylisotonitazene (norisotonitazene) is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2023 as an active metabolite of the closely related compound isotonitazene, and was found to have similar potency. It is one of the strongest benzimidazole opioids discovered, with an analgesic strength 20 times stronger than fentanyl. Starting in 2023, it has become an increasingly widespread drug of abuse in its own right, linked to numerous overdose cases, and may be considered an analog of the schedule 1 drug metonitazene. In October 2023, the DEA published an intent to temporarily schedule etonitazepipne and N-desethylisotonitazene. As of April 2024, it is not yet controlled in the United States.
From November 1998 to March 1999, McGregor starred as Malcolm Scrawdyke in a revival of David Halliwell's Little Malcolm and His Struggles Against the Eunuchs, directed by his uncle, Denis Lawson. The production was first staged at the Hampstead Theatre before transferring to the Comedy Theatre in London's West End. In November 2001, McGregor made a cameo appearance in The Play What I Wrote. From June 2005 to April 2007, McGregor starred alongside Jane Krakowski, Douglas Hodge and Jenna Russell in the Donmar Warehouse revival of Guys and Dolls after it transferred to the Piccadilly Theatre in London. He played the leading role of Sky Masterson. McGregor received the LastMinute.com award for Best Actor for his performance in 2005, and he was nominated for a Laurence Olivier Award for Best Actor in a Musical in 2007. From December 2007 to February 2008, McGregor starred as Iago in Othello at the Donmar Warehouse alongside Chiwetel Ejiofor as Othello and Kelly Reilly as Desdemona. He reprised the role on BBC Radio 3 in May 2008. McGregor made his Broadway debut in a 2014 production of Tom Stoppard's The Real Thing at the American Airlines Theatre. He was cast in the role of Henry and starred alongside Maggie Gyllenhaal and Cynthia Nixon. McGregor returned to the West End in April 2025, to act in My Master Builder, a new play based on Henrik Ibsen's "The Master Builder". In 2027, he is expected to star in the 2027 play Supernova at Pitlochry Festival Theatre.
=== Anti-mutagenic === In one study, bemethyl was shown to prevent the mutagenic effect of white asbestos in mice and in cultured human whole blood. A study using mice showed bemethyl to reduce mutation induced by certain mutagenic drugs. Another study using cells from human donors showed Bemethyl to be anticlastogenic (able to minimize chromosome breakages).
Sources: en.wikipedia.org
==== Rotary jet spinning ==== Rotary jet spinning is a technique used in the production of biotextiles, which involves the extrusion of polymer solutions or melts through a rapidly rotating spinneret. As the polymer solution or melt exits the spinneret, it is subjected to centrifugal forces, forming fine fibers. These fibers are collected to create a nonwoven fabric or scaffold structure suitable for various biomedical applications. Rotary jet spinning offers advantages such as producing highly porous structures with controllable fiber diameter and alignment, making it promising for tissue engineering and drug delivery applications in biomedicine.
ADP + phosphate + NADPH In humans, this enzyme is encoded by the gene NAXD. This enzyme belongs to the family of lyases, specifically the hydro-lyases, which cleave carbon-oxygen bonds. The systematic name of this enzyme class is (6S)-6-β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ATP-hydrolysing; NADH-forming). Other names in common use include reduced nicotinamide adenine dinucleotide hydrate dehydratase, ATP-dependent H4NAD(P)+OH dehydratase, (6S)-β-6-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-, and dinucleotide hydro-lyase (ATP-hydrolysing).
Lysis ( LY-sis; from Greek λῠ́σῐς lýsis 'loosening') is the breaking down of the membrane of a cell, often by viral, enzymic, or osmotic (that is, "lytic" LIT-ik) mechanisms that compromise its integrity. A fluid containing the contents of lysed cells is called a lysate. In molecular biology, biochemistry, and cell biology laboratories, cell cultures may be subjected to lysis in the process of purifying their components, as in protein purification, DNA extraction, RNA extraction, or in purifying organelles. Many species of bacteria are subject to lysis by the enzyme lysozyme, found in animal saliva, egg white, and other secretions. Phage lytic enzymes (lysins) produced during bacteriophage infection are responsible for the ability of these viruses to lyse bacterial cells. Penicillin and related β-lactam antibiotics cause the death of bacteria through enzyme-mediated lysis that occurs after the drug causes the bacterium to form a defective cell wall. If the cell wall is completely lost and the penicillin was used on gram-positive bacteria, then the bacterium is referred to as a protoplast, but if penicillin was used on gram-negative bacteria, then it is called a spheroplast.
Unless the volume of a liquid exactly matches the volume of its container, one or more surfaces are observed. The presence of a surface introduces new phenomena which are not present in a bulk liquid. This is because a molecule at a surface possesses bonds with other liquid molecules only on the inner side of the surface, which implies a net force pulling surface molecules inward. Equivalently, this force can be described in terms of energy: there is a fixed amount of energy associated with forming a surface of a given area. This quantity is a material property called the surface tension, in units of energy per unit area (SI units: J/m2). Liquids with strong intermolecular forces tend to have large surface tensions. A practical implication of surface tension is that liquids tend to minimize their surface area, forming spherical drops and bubbles unless other constraints are present. Surface tension is responsible for a range of other phenomena as well, including surface waves, capillary action, wetting, and ripples. In liquids under nanoscale confinement, surface effects can play a dominating role since – compared with a macroscopic sample of liquid – a much greater fraction of molecules are located near a surface. The surface tension of a liquid directly affects its wettability.
Sources: en.wikipedia.org
{\displaystyle \nabla \cdot {\boldsymbol {\tau }}=2\mu \nabla \cdot {\boldsymbol {\varepsilon }}=\mu \nabla \cdot \left(\nabla \mathbf {u} +\nabla \mathbf {u} ^{\mathsf {T}}\right)=\mu \,\nabla ^{2}\mathbf {u} }
Vacuum evaporation is the process of causing the pressure in a liquid-filled container to be reduced below the vapor pressure of the liquid, causing the liquid to evaporate at a lower temperature than normal. Although the process can be applied to any type of liquid at any vapor pressure, it is generally used to describe the boiling of water by lowering the container's internal pressure below standard atmospheric pressure and causing the water to boil at room temperature. The vacuum evaporation treatment process consists of reducing the interior pressure of the evaporation chamber below atmospheric pressure. This reduces the boiling point of the liquid to be evaporated, thereby reducing or eliminating the need for heat in both the boiling and condensation processes. There are other advantages, such as the ability to distill liquids with high boiling points and avoiding decomposition of substances that are heat sensitive.
== Adverse drug reactions == Central nervous system adverse effects do not tend to occur due to poor penetration across the blood brain barrier, although a slight raising of prolactin levels may occur. Raising of prolactin levels is more common with high dose regimes of itopride.
== History == Phage display was first described by George P. Smith in 1985, when he demonstrated the display of peptides on filamentous phage (long, thin viruses that infect bacteria) by fusing the virus's capsid protein to one peptide out of a collection of peptide sequences. This displayed the different peptides on the outer surfaces of the collection of viral clones, where the screening step of the process isolated the peptides with the highest binding affinity. In 1988, Stephen Parmley and George Smith described biopanning for affinity selection and demonstrated that recursive rounds of selection could enrich for clones present at 1 in a billion or less. In 1990, Jamie Scott and George Smith described creation of large random peptide libraries displayed on filamentous phage. Phage display technology was further developed and improved by groups at the Laboratory of Molecular Biology with Greg Winter and John McCafferty, The Scripps Research Institute with Richard Lerner and Carlos Barbas and the German Cancer Research Center with Frank Breitling and Stefan Dübel for display of proteins such as antibodies for therapeutic protein engineering. Smith and Winter were awarded a half share of the 2018 Nobel Prize in chemistry for their contribution to developing phage display. A patent by George Pieczenik claiming priority from 1985 also describes the generation of peptide libraries.
catalyst Any element or compound that facilitates an increase in the rate of a chemical reaction but which is not consumed or destroyed during the reaction. It is considered both a reactant and a product of the reaction.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.